Results for Activators & Inhibitors ( 18112 )
- Ref: T4S0295Sizes: 1 g, 5 mg, 25 mg, 100 mg, 50 mg, 500 mg, 10 mg, 1 mL * 10 mM (in DMSO)
- From: €55.00
Licochalcone B (Legacy Tebubio ref. 282T4S0350). 1. Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. 2. LCB and Licochalcone D(LCD) significantly reduced the LPS-induced production of NO, TNFalpha and MCP-1. 3. A novel LCB derivative compound: (E)-3-(3, 4-dihydroxy-2-methoxyphenyl)-1-(2, 4-dihydroxyphenyl)prop-2-en-1-one inhibits inflammatory reactions in macrophages and protects mice from endotoxin shock.
- From: €52.00
Glaucocalyxin A (Legacy Tebubio ref. 282T4S0498). 1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.